Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals.

Many men have breast symptoms, including enlarged or painful breast tissue, but the majority do not need a mammogram, say researchers from Mayo Clinic Cancer Center. Mammograms are used to check for the presence of breast cancers, which are very rare in males.

Reducing dietary fat intake may decrease the chance of a breast cancer recurrence in women who have been treated for early-stage breast cancer, according to a randomized, phase III trial in the December 20 issue of the Journal of the National Cancer Institute.

Nation-wide statistics indicate that while some types of cancer are occurring less frequently, the rates of others are still surging upward.

Treatment with Aromasin after five years of tamoxifen results in significant improvement in relapse-free survival

Expression of two different proteins taken from primary tumor biopsies is highly associated with spread of breast cancer to nearby lymph nodes, according to researchers who say this protein profile could help identify at an early stage those patients whose disease is likely to metastasize.

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.

In 2003, breast cancer incidence in the United States dropped sharply, and this decline may largely be due to the fact that millions of older women stopped using hormone replacement therapy (HRT) in 2002, according to a new analysis led by researchers at The University of Texas M. D. Anderson Cancer Center.

First multi-center clinical trial conducted for women with this rare disease

TEACH study is phase III trial of new targeted drug Tykerb for HER2-positive tumors

Inflammatory breast cancer (IBC) is the deadliest form of the disease, with fewer than half of those diagnosed today having a five-year prognosis for survival. To find out what drives this most aggressive of human breast cancers, and to rapidly screen for drugs that might stop IBC, researchers at the University of California, San Diego (UCSD), have come up with an unlikely yet extremely promising ally: a transparent fish suitable for xenografts.

A gift of $800,000 from the Seattle division of Safeway Inc. to the Seattle Cancer Care Alliance (SCCA) will bring a mobile-mammography clinic with the latest diagnostic-technology tools to women who may not otherwise be screened for breast cancer.